UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 350

Sortiert nach

Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug

JNCI : Journal of the National Cancer Institute, 2012-09, Vol.104 (17), p.1320-1334

2012

Volltextzugriff (PDF)

PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System

Clinical cancer research, 2013-10, Vol.19 (19), p.5413-5422

2013

Volltextzugriff (PDF)

HER2 missense mutations have distinct effects on oncogenic signaling and migration

Proceedings of the National Academy of Sciences - PNAS, 2015-11, Vol.112 (45), p.E6205-E6214

2015

Volltextzugriff (PDF)

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

The Journal of clinical investigation, 2022-12, Vol.132 (23)

2022

Volltextzugriff (PDF)

Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones

The Journal of clinical investigation, 2021-03, Vol.131 (6), p.1-10

2021

Volltextzugriff (PDF)

Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC

Cancers, 2021-11, Vol.13 (21), p.5509

2021

Volltextzugriff (PDF)

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

Science translational medicine, 2012-06, Vol.4 (140), p.140ra86

2012

Volltextzugriff (PDF)

GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers

Oncotarget, 2017-11, Vol.8 (61), p.103415-103427

2017

Volltextzugriff (PDF)

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

Oncotarget, 2016-02, Vol.7 (5), p.6281-6293

2016

Volltextzugriff (PDF)

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers

Proceedings of the National Academy of Sciences - PNAS, 2014-12, Vol.111 (49), p.17606-17611

2014

Volltextzugriff (PDF)

Single Copies of Mutant KRAS and Mutant PIK3CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation

Cancer research (Chicago, Ill.), 2013-06, Vol.73 (11), p.3248-3261

2013

Volltextzugriff (PDF)

Knockin of mutant PIK3CA activates multiple oncogenic pathways

Proceedings of the National Academy of Sciences - PNAS, 2009-02, Vol.106 (8), p.2835-2840

2009

Volltextzugriff (PDF)

Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244

The journal of clinical endocrinology and metabolism, 2007-12, Vol.92 (12), p.4712-4718

2007

Volltextzugriff (PDF)

NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability

Proceedings of the National Academy of Sciences - PNAS, 2015-09, Vol.112 (37), p.11583-11588

2015

Volltextzugriff (PDF)

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

Oncotarget, 2014-09, Vol.5 (18), p.8093-8106

2014

Volltextzugriff (PDF)

A prostate-specific antigen–activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer

Molecular cancer therapeutics, 2007-11, Vol.6 (11), p.2928-2937

2007

Volltextzugriff (PDF)

Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762)

Journal of clinical oncology, 2006-04, Vol.24 (12), p.1846-1851

2006

Volltextzugriff (PDF)

Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives

Bioorganic & medicinal chemistry, 2017-12, Vol.25 (24), p.6707-6717

2017

Volltextzugriff (PDF)

Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer

The journal of clinical endocrinology and metabolism, 2006-01, Vol.91 (1), p.79-84

2006

Volltextzugriff (PDF)

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study

The Prostate, 2016-09, Vol.76 (13), p.1218-1226

2016

Volltextzugriff (PDF)

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

The Prostate, 2003-03, Vol.54 (4), p.249-257

2003

Volltextzugriff (PDF)

Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy

The Prostate, 2016-06, Vol.76 (8), p.703-714

2016

Volltextzugriff (PDF)

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

Molecular cancer therapeutics, 2020-11, Vol.19 (11), p.2353-2362

2020

Volltextzugriff (PDF)

Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer

The journal of clinical endocrinology and metabolism, 2009-10, Vol.94 (10), p.4107-4112

2009

Volltextzugriff (PDF)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2–activated prodrug as targeted therapy for prostate cancer

Molecular cancer therapeutics, 2004-11, Vol.3 (11), p.1439-1450

2004

Volltextzugriff (PDF)

1 – 25 von 350

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(321)
Mit Volltextzugriff
(307)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Targeting Carcinoma-Associated Fibroblasts Within the Tumor Stroma With a Fibroblast Activation Protein-Activated Prodrug

PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System

HER2 missense mutations have distinct effects on oncogenic signaling and migration

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones

Post-Hypoxic Cells Promote Metastatic Recurrence after Chemotherapy Treatment in TNBC

Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy

GATA3 frameshift mutation promotes tumor growth in human luminal breast cancer cells and induces transcriptional changes seen in primary GATA3 mutant breast cancers

Ki-67 is required for maintenance of cancer stem cells but not cell proliferation

MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers

Single Copies of Mutant KRAS and Mutant PIK3CA Cooperate in Immortalized Human Epithelial Cells to Induce Tumor Formation

Knockin of mutant PIK3CA activates multiple oncogenic pathways

Selective Growth Inhibition in BRAF Mutant Thyroid Cancer by the Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244

NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability

Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment

A prostate-specific antigen–activated N-(2-hydroxypropyl) methacrylamide copolymer prodrug as dual-targeted therapy for prostate cancer

Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762)

Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives

Activity of Irinotecan and the Tyrosine Kinase Inhibitor CEP-751 in Medullary Thyroid Cancer

Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy

Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer

Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer

Screening a combinatorial peptide library to develop a human glandular kallikrein 2–activated prodrug as targeted therapy for prostate cancer

Suchergebnisse filtern